30-Apr-2026
mbiomics reaches 30 million euros with third closing of Series A round
TechBio start-up develops oral microbiome therapeutics from living bacterial strains
mbiomics GmbH, a TechBio company developing scalable, microbiome-based therapeutics for severe and chronic diseases, announced the successful third closing of its Series A financing round of EUR 12 million, bringing the total volume of the round to EUR 30 million. Several existing investors, ...
chronic diseases
clinical trials
gut microbiome